Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azacitidine - Pfizer

Drug Profile

Azacitidine - Pfizer

Alternative Names: 5-azacytidine; Aza-C; Azacytidine; CC-486; Ladakamycin; NS-17; NSC-102816; U-18496; VIDAZA; Vidaza

Latest Information Update: 16 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacia Corporation
  • Developer Australasian Leukaemia & Lymphoma Group; Bristol-Myers Squibb; Celgene Corporation; Columbia University; H. Lee Moffitt Cancer Center and Research Institute; Karolinska University Hospital; Kirby Institute for infection and immunity in society; Medical University of South Carolina; Nippon Shinyaku; Pfizer; University Hospital Regensburg; University of Bologna; University of California, San Diego; University of Colorado at Denver; University of Kansas Medical Center; University of Leipzig; University of Texas M. D. Anderson Cancer Center; University of Utah; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase III T-cell lymphoma
  • Phase II Breast cancer; Graft-versus-host disease; Leukaemia; Nasopharyngeal cancer; Non-small cell lung cancer; Peripheral T-cell lymphoma
  • Phase I/II Colorectal cancer; Diffuse large B cell lymphoma; Renal cancer; Solid tumours
  • Phase I Lymphoma
  • No development reported Multiple myeloma

Most Recent Events

  • 12 Sep 2019 Celgene plans to submit a regulatory application for Acute myeloid leukaemia in the first half of 2020 (PO)
  • 12 Sep 2019 Efficacy and adverse events data from the phase III QUAZAR AML-001 trial in Acute myeloid leukaemia released by Celgene
  • 07 Aug 2019 Celgene completes enrolment in a phase I/II trial for Chronic myeloid leukemia in USA (NCT01460498)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top